# US 9,782,459 B2 · Eosinophil peroxidase compositions and methods of their use > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,782,459 B2 - Document ID: US9782459B2 - Status: Granted - Kind: B2 - Application number: 14/150,619 - Filed: 2014-01-08 - Published: 2014-05-01 - Granted: 2017-10-10 - Earliest claimed: 2011-07-11 - Assignees: ExOxEmis, Inc. - Applicants: Exoxemis, Inc. - Inventors: Jackson T. Stephens, Jr.; Matthew J. Pete - Web page: https://patentgrep.com/patent/US9782459B2 ## CPC - A61K 38/44: Oxidoreductases (1) - A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) - A61K 31/327: Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids - A61K 31/401: Proline; Derivatives thereof, e.g. captopril - A61K 33/40: Peroxides - A61K 38/443: {acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)} - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 17/00: Drugs for dermatological disorders - A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics - A61P 31/04: Antibacterial agents - A61P 35/00: Antineoplastic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - C12Y 101/03004: Glucose oxidase (1.1.3.4) - C12Y 111/01007: Peroxidase (1.11.1.7), i.e. horseradish-peroxidase - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C12Y: ENZYMES ## Abstract Eosinophil peroxidase compositions and methods of their use for killing and/or inhibiting the growth of susceptible microorganisms are provided. The compositions include an eosinophil peroxidase, a peroxide or peroxide source, and amino acids glycine, L-alanine, and L-proline. ## Claims ### Claim 1 A composition for killing or inhibiting the growth of non-sporular bacteria, comprising: (a) an eosinophil peroxidase; (b) glucose oxidase; and (c) amino acids glycine, L-alanine, and L-proline, wherein the amino acids enhance the antibacterial activity of the eosinophil peroxidase. ### Claim 2 (depends on 1) The composition of claim 1, further comprising a bromide. ### Claim 3 (depends on 1) The composition of claim 1, comprising from about 0.1 to about 1,000 μg/ml of eosinophil peroxidase. ### Claim 4 (depends on 1) The composition of claim 1, comprising from about 0.1 to about 500 mM of each amino acid. ### Claim 5 (depends on 1) The composition of claim 1, comprising from about 1 to about 500 U/ml of glucose oxidase. ### Claim 6 (depends on 1) A method for killing or inhibiting the growth of non-sporular bacteria comprising, contacting the non-sporular bacteria with an effective amount of a composition of claim 1. ### Claim 7 (depends on 1) A method of treating a non-sporular bacterial infection in a human or animal subject, comprising administering to the site of infection an effective amount of a composition of claim 1. ### Claim 8 (depends on 1) A method of treating a non-sporular bacterial infection of a surgical site in a human or animal subject, comprising administering to the surgical site an effective amount of a composition of claim 1. ### Claim 9 (depends on 8) The method of claim 8, wherein the surgical site is a cancer surgical site. ### Claim 10 (depends on 9) The method of claim 9, wherein the cancer surgical site is a colorectal cancer surgical site. ### Claim 11 (depends on 9) The method of claim 9, wherein the cancer surgical site is a brain cancer surgical site. ### Claim 12 (depends on 8) The method of claim 8, wherein the surgical site is a laparoscopic surgical site. ### Claim 13 (depends on 7) The method of claim 7, wherein the non-sporular bacterial infection is a multidrug resistant infection. ### Claim 14 A binary combination for killing or inhibiting the growth of non-sporular bacteria, comprising: (a) a first composition comprising an eosinophil peroxidase; glucose oxidase; and amino acids glycine, L-alanine, and L-proline, wherein the amino acids enhance the antibacterial activity of the eosinophil peroxidase; and (b) a second composition comprising glucose, wherein the binary combination is effective for killing or inhibiting the growth of non-sporular bacteria when the first composition and the second composition are combined in a single solution and come in contact with the non-sporular bacteria. ### Claim 15 (depends on 14) The binary combination of claim 14, wherein the first composition, the second composition, or both the first composition and the second composition further comprise a bromide. ### Claim 16 A binary combination for killing or inhibiting the growth of non-sporular bacteria, comprising: (a) a first composition comprising an eosinophil peroxidase; glucose oxidase; and amino acids glycine, L-alanine, and L-proline, wherein the amino acids enhance the antibacterial activity of the eosinophil peroxidase; and (b) a second composition comprising glucose, wherein the binary combination is effective for killing or inhibiting the growth of non-sporular bacteria when the first composition and the second composition are each in solution form and are applied concurrently to the non-sporular bacteria. ### Claim 17 A binary combination for killing or inhibiting the growth of non-sporular bacteria, comprising: (a) a first composition comprising an eosinophil peroxidase; glucose oxidase; and amino acids glycine, L-alanine, and L-proline, wherein the amino acids enhance the antibacterial activity of the eosinophil peroxidase; and (b) a second composition comprising glucose, wherein the binary combination is effective for killing or inhibiting the growth of non-sporular bacteria when the first composition and the second composition are each in solution form and are applied sequentially to the non-sporular bacteria.